Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

We are a premier specialty pharmaceutical company providing innovative therapeutics to patients. Our focus is on improving patient outcomes by developing and responsibly commercializing differentiated products through unique drug delivery systems for CNS disorders and pain.

We broadly leverage our drug delivery technologies with partners for the benefit of physicians and patients in other therapeutic areas. We are building an organization that makes a difference in t... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix January 2014 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.71
Change (%) Stock is Down 0.11 (3.90%)
Volume3,848,414
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
04/15/14Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Blocked Access to Zohydro™ ER
SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro™ ER on Constitutional grounds.  This order will become effective on April 22, 2014. The court decision today supports the importance of... 
Printer Friendly Version
04/11/14Let's Get the Facts Straight About Zohydro™ ER--and the Important Patient Need It Fills
SAN DIEGO, April 11, 2014 /PRNewswire/ -- Rampant misinformation about Zohydro™ ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence. Let's get the facts straight Zohydro ER is the first and onl... 
Printer Friendly Version
04/08/14Zogenix Update on Legal Action
SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro™ ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for... 
Printer Friendly Version
04/07/14Zogenix Takes Legal Action in Federal Court to Block Massachusetts Improper Ban on Zohydro™ ER
Company Files for Injunction - Prescription Drug Status Should Reside Solely With the FDA SAN DIEGO, April 7, 2014 /PRNewswire/ --  Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by G... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.